ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2179

Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey

Sara McCoy1, Alan Baer2, Ann Xi3, Corey Moorhead4, Giorgio Castellano4, Anthony Amatucci5, Ilias Alevizos6 and Haridarshan Patel7, 1University of Wisconsin School of Medicine and Public Health, Middleton, WI, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Horizon Therapeutics, Indianapolis, IN, 4Adelphi Real World, Bollington, United Kingdom, 5Horizon Therapeutics, Cambridge, MA, 6Horizon Therapeutics, Rockville, MD, 7Horizon Therapeutics, Deerfield, IL

Meeting: ACR Convergence 2023

Keywords: Patient reported outcomes, quality of life, Sjögren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjögren’s disease (SjD) is a debilitating disease that has been shown to impact patients’ quality of life (QoL). Though oral and ocular dryness are well-recognized causes of reduced QoL, there is limited evidence on impact of dental decay and vaginal dryness on QoL. Our study aims to describe the disease burden of patients with SjD, as measured by clinical testing and patient-reported outcome (PRO) measures in real-world clinical settings.

Methods: Data were drawn from the 2018 Adelphi Primary Sjögren’s Disease Specific Programme™, a cross-sectional survey with retrospective data collection of rheumatologists and their consulting patients with SjD in France, Germany, Italy, Spain and the United States. Rheumatologists completed patient record forms for their next 6 primary SjD patients with systemic disease activity and reported on patient demographics, clinical characteristics, and patient assessments. Patients were invited to complete a form capturing PROs, including EQ-5D-3L, the Work Productivity and Activity Impairment Questionnaire (WPAI), and Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F). QoL, work productivity, and fatigue were evaluated and all data were analyzed descriptively.

Results: 316 rheumatologists provided data for 1,879 patients: mean [SD] age 53 [12] years, 89% female, 89% White. Patients had a mean [SD] of 13 [7] tests leading up to diagnosis and 7 [12] consultations in the past 12 months. Patients are most commonly co-managed by PCP/GPs (48%) and ophthalmologists (47%), with other health care professional types co-managing < 20% of patients. Rheumatologists recorded dry eyes, physical fatigue, and dry mouth as the most common symptoms in 91%, 77%, and 71% of patients respectively. Of note, 22% of patients reported dental decay and nearly 1 in 3 female patients experienced vaginal dryness (Table 1). EQ-5D-3L utility, EQ-5D-3L VAS, and FACIT-F scores were 0.741, 63.5 and 31.3 across all SjD patients respectively, compared to the population norms of 0.867, 79.3 and 43.5. Patients with SjD experiencing dental decay or vaginal dryness reported lower PRO scores than the overall SjD population (Table 2).

Conclusion: Analyses from this multinational survey revealed that patients with SjD are burdened with multiple diagnostic tests and physician consultations to manage their symptoms following diagnosis. There is a substantial impact of SjD on patients’ general QoL, fatigue, and work productivity, which is worsened in patients with dental decay or vaginal dryness, which highlights the systemic nature of dryness and downstream consequences of oral dryness. These findings suggest an unmet need among patients with SjD, who may require additional management by dentists or sexual health professionals who currently have limited involvement in patient care.

Supporting image 1

Table 1. Physician-reported symptoms in patients with Sjögren’s disease at the time of data collection.

Supporting image 2

Table 2. Patient reported outcome (PRO) scores for all patients with Sjögren’s disease (SjD), SjD patients with dental decay and SjD patients with vaginal dryness.

Note that base size fluctuates due to data completeness for all variables.

The EQ-5D_3L Utility score is measured on a scale of 0_1 where 1 indicates full health and 0 death. The EQ-VAS is measured on a 0_100 scale with 100 indicating full health. The FACIT-Fatigue is measured on a scale of 0-52 where lower scores indicate more severe fatigue. EQ-5D_3L Utility and EQ-VAS population norms are taken from Janssen, MF et al., 2019 (https://doi.org/10.1007/s10198-018-0955-5), and the FACIT-Fatigue population norm from Montan et al., 2018 (https://doi.org/10.1016/j.jval.2018.03.013). WPAI is measured using a series of questions asked to patients about how their disease affects their work and normal activities. Absenteeism refers to work time missed due to disease. Presenteeism refers to impairment whilst working due to disease.

FACIT: Functional assessment of chronic illness therapy; SD: standard deviation; US: United States; VAS: visual analogue scale


Disclosures: S. McCoy: Bristol-Myers Squibb(BMS), 2, Horizon, 2, Kiniksa, 2, Novartis, 2, Otsuka/Visterra, 2, Target RWE, 2; A. Baer: Bristol-Myers Squibb(BMS), 2; A. Xi: Horizon Therapeutics, 3, 11; C. Moorhead: None; G. Castellano: None; A. Amatucci: Horizon Therapeutics, 3, 11; I. Alevizos: Horizon Therapeutics, 3, 11; H. Patel: Horizon Therapeutics, 3, 12, Stockholder.

To cite this abstract in AMA style:

McCoy S, Baer A, Xi A, Moorhead C, Castellano G, Amatucci A, Alevizos I, Patel H. Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/disease-burden-of-patients-with-primary-sjogrens-disease-results-from-a-multinational-real-world-survey/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-burden-of-patients-with-primary-sjogrens-disease-results-from-a-multinational-real-world-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology